Patents

Upcoming copyright and patent talks

Ben Fitzpatrick will be giving his highly regarded annual update of patents for IPSANZ on 16 July at 12.15 at the RACV Club in Melbourne.

Details will be available here (in due course).

After talking in Melbourne on 3 August, Dr Gurry will be delivering a speech at the National Press Club in Canberra on 4 August and then

on 6 August, the keynote speech at the Reimagining copyright for the 21st century in Canberra at the National Gallery. In what promises to be an exciting conference, there will also be papers by:

  • Professor Brad Sherman: Key developments in the last 40 years of copyright
    that shape our thinking about the future
    * Professor Sam Ricketson: Copyright and functional products
    * Sophie Goddard SC: Development of copyright by the courts
    * Dr Matthew Rimmer: The role of fair use in creative freedom
    * Associate Professor Melissa de Zwart:The role of copyright in innovation
  • Professor Brad Sherman: Key developments in the last 40 years of copyright that shape our thinking about the future
  • Professor Sam Ricketson: Copyright and functional products
  • Sophie Goddard SC: Development of copyright by the courts
  • Dr Matthew Rimmer: The role of fair use in creative freedom
  • Associate Professor Melissa de Zwart:The role of copyright in innovation

More details from here.

Finally, details about the biennal Copyright Society Symposium on 14 and 15 October 2009 in Sydney are up here.

Upcoming copyright and patent talks Read More »

US patent instructions

A committee comprised of judges and attorneys has published the National Patent Jury Instructions.

As its name suggests, a set of model instructions for juries in the USA for patent actions.

Apart from when your client might be litigating in lawyer paradise, you never know, you might find some useful ideas – bearing in mind that their law and our law are not exactly the same!

Download from here. Lid dip Patently-O.

US patent instructions Read More »

Patent and Trade Mark procedures in the Office

IP Australia has released 3 further consultation papers on “IP Rights Reforms”:

  • resolving divisional applications faster
  • resolving patent oppositions faster
  • resolving trade mark oppositions faster

Submissions are sought by 17 August 2009.

Download the papers (pdf or .doc) from here.

There are also links to the earlier papers on ‘Getting the Balance Right’ and ‘Exemptions to Patent Infringement’.

Patent and Trade Mark procedures in the Office Read More »

Re-examining a patent

VIP Plastic Packaging is suing BMW Plastics for infringing the former’s standard patent for a “Variable-length dip tube for a fluid transfer container”.

BMW Plastics denies infringement and has counter-claimed for invalidity.

Now, Kenny J has refused BMW Plastics’ attempt to get an order to have the Commissioner re-examine VIP Plastic Packaging’s patent.

Section 97 provides for re-examination of a standard “patent” in 3 situations:

  1. following acceptance, but prior to grant;
  2. following grant (when no other relevant proceedings are on foot in the Court); or
  3. following a direction from the Court in the course of relevant proceedings.

In the first situation, the Commissioner can refuse to grant the patent following re-examination. In the second, the Commissioner can revoke. In the third, the Commissioner just prepares a report which (presumably) forms part of the evidence before the Court.

As reported by her Honour, BMW Plastics’ thinking was that the Commissioner could provide the benefit of technical expertise which the Court might otherwise not have and there might be a costs saving. To this end, it was prepared to undertake not to contest the findings of the Commissioner’s report. VIP Plastic Packaging refused to reciprocate and, rather heroically, BMW Plastics contended that Court should order VIP Plastic Packaging to be bound too.

Kenny J was (with respect) justifiably sceptical about the costs savings that might flow:

I doubt that the provision of a report by the Commissioner after re-examination would reduce the cost of this proceeding and expedite its determination. First, the Commissioner’s report after re-examination is not binding on the Court. In the absence of an undertaking of the kind sought by B.M.W. Plastics from VIP Plastic, the provision of a report under s 100 will not necessarily relieve the Court of the task of deciding the issues of novelty and lack of inventive step by reference to the admissible evidence. If the Commissioner’s report were unfavourable to VIP Plastic, it would desire to put on evidence and dispute the report. There may be additional issues for the Court to determine if it receives such a report. Further, both parties said that, regardless of the lack of novelty and inventive step grounds, there will be a need for evidence, including expert evidence, to be adduced before the Court on various other issues. In the circumstances, I am not persuaded that re-examination by the Commissioner would be most expeditious or reduce costs.

(my underlining)

VIP Plastic Packaging Pty Ltd v BMW Plastics Pty Ltd [2009] FCA 593

Re-examining a patent Read More »

Bilski v Doll

The US Supreme Court granted certiorari overnight. So, we’ll eventually get to find out about the patentability of business methods in the US.

Patently-O reports the questions are:

Whether the Federal Circuit erred by holding that a “process” must be tied to a particular machine or apparatus, or transform a particular article into a different state or thing (“machine-or-transformation” test), to be eligible for patenting under 35 U.S.C. § 101, despite this Court’s precedent declining to limit the broad statutory grant of patent eligibility for “any” new and useful process beyond excluding patents for “laws of nature, physical phenomena, and abstract ideas.”

Whether the Federal Circuit’s “machine-or-transformation” test for patent eligibility, which effectively forecloses meaningful patent protection to many business methods, contradicts the clear Congressional intent that patents protect “method[s] of doing or conducting business.” 35 U.S.C. § 273.

Scotusblog has links to the docket and the rounds of briefs here.

The comments on Patently-O anticipate the end of State Street and business methods in the USA.

Bilski v Doll Read More »

IPRIA seminar on patent infringementi

IPRIA (Ass. Prof. Beth Webster and Kimberlee Weatherall) is holding a lunch time seminar reporting on the results of their survey of patent infringement in Australia:

  • in Melbourne on 9 June 2009; and
  • in Brisbane on 10 June,

at the Blake Dawson offices in those cities.

According to the blurb:

One of the great unknowns of patent policy is how much infringement actually goes on, and how much of that infringement leads to enforcement of an informal or formal kind. IPRIA recently conducted a representative survey of over 3700 Australian inventors in order to estimate the prevalence of (alleged) infringement and what formal and informal steps were taken to stop the copying activities. We present these findings along with a discussion of what can be done to improve the efficacy of patent enforcement in Australia.

The seminar is free of charge.

More information and links to the registration pages for each event here.

IPRIA seminar on patent infringementi Read More »

Working a patent for regulatory approvals

Patently-O considers a new Federal Circuit case in the USA dealing with the scope of s 271(e)(1) – a defence to infringement by working the patent to prepare regulatory data.

It would appear that the defence should now apply in proceedings against imports before the ITC.

Patents Act 1990 (Cth) s 119A (introduced with effect from 25 October 2006 following ACIP’s report) permits such activity where the working:

  • is for purposes of having a therapeutic pharmaceutical product included in the Australian Register of Therapeutic Goods;
  • or a similar foreign regulatory approval.

Although working for a foreign regulatory approval may take place only in the supplementary protection period (see e.g. ACIP on experimental use p. 44 (pdf)).

See now Alphapharm Pty Ltd v H Lundbeck A/S [2008] FCA 559 at [643]ff.

IP Australia is considering extending this: see paragraphs 9 and 17 of IP Australia’s Consultation Paper on experimental use (pdf) [NOTE: submissions should be in by 8 May 2009. Submissions on the Getting the Balance Right paper (pdf) are also due by then.]

WIPO’s Standing Committee on Patents has a study paper on exceptions and limitations as an area of increased focus.

Working a patent for regulatory approvals Read More »

Patents, pharmaceuticals and exports

I’m not quite sure why, but the blogosphere is increasingly chattering again about relaxing the rules against infringing a patent by making the protected product (esp. a pharmaceutical) for export:

IP’s What’s Up reviews the TRIPS status including the DOHA declaration and its rather tentative take up.

Patents, pharmaceuticals and exports Read More »

IPRIA and gene patents

IPRIA and gene patents Read More »

Should genes be patented?

Should genes be patented? Read More »